Overview Financials News + Filings Key Docs Charts Holdings Ownership Insiders
All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Inv. presentation
Quarterly results
Director comp.
Acq. announced
Consulting agrmnt
Director departure
CC transcript
|
|
NxStage Medical, Inc. (NXTM)
|
Create: Alert |
All | News | Filings
| Date Filed | Type | Description |
| 04/24/2020 |
CT ORDER
| Form CT ORDER - Confidential treatment order: |
| 12/31/2019 |
CT ORDER
| Form CT ORDER - Confidential treatment order: |
| 12/31/2019 |
CT ORDER
| Form CT ORDER - Confidential treatment order: |
| 12/31/2019 |
CT ORDER
| Form CT ORDER - Confidential treatment order: |
| 12/31/2019 |
CT ORDER
| Form CT ORDER - Confidential treatment order: |
| 12/23/2019 |
SC 13G/A
| Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] |
| 10/03/2019 |
CT ORDER
| Form CT ORDER - Confidential treatment order: |
| 06/05/2019 |
CT ORDER
| Form CT ORDER - Confidential treatment order: |
| 03/05/2019 |
15-12G
| Form 15-12G - Securities registration termination [Section 12(g)]: |
| 02/25/2019 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 02/25/2019 |
4
| Burbank Jeffrey H (CEO) has filed a Form 4 on NxStage Medical, Inc.|
Txns:
| Disposed/sold 781,646 shares
@ $30, valued at
$23.4M
Disposed/sold 39,062 options to buy
@ $18.48, valued at
$721.9k
Disposed/sold 189,456 options to buy
@ $11.03, valued at
$2.1M
Disposed/sold 175,256 options to buy
@ $14.66, valued at
$2.6M
Disposed/sold 205,058 options to buy
@ $16.66, valued at
$3.4M
Disposed/sold 268,159 options to buy
@ $15.58, valued at
$4.2M
Disposed/sold 149,567 options to buy
@ $27.89, valued at
$4.2M
Disposed/sold 34,928 restricted stock units
@ $0 |
|
| 02/25/2019 |
4
| TOWSE MATTHEW W (SVP and Chief Financial Office) has filed a Form 4 on NxStage Medical, Inc.|
Txns:
| Disposed/sold 28,396 shares
@ $30, valued at
$851.9k
Disposed/sold 60,958 options to buy
@ $14.66, valued at
$893.6k
Disposed/sold 65,618 options to buy
@ $16.66, valued at
$1.1M
Disposed/sold 89,386 options to buy
@ $15.58, valued at
$1.4M
Disposed/sold 49,855 options to buy
@ $27.89, valued at
$1.4M
Disposed/sold 11,643 restricted stock units
@ $0 |
|
| 02/25/2019 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 02/25/2019 |
4
| Mixer Jean K (Director) has filed a Form 4 on NxStage Medical, Inc.|
Txns:
| Disposed/sold 16,012 shares
@ $30, valued at
$480.4k
Disposed/sold 23,394 options to buy
@ $13.16, valued at
$307.9k
Disposed/sold 19,724 options to buy
@ $16.81, valued at
$331.6k
Disposed/sold 15,854 options to buy
@ $18.32, valued at
$290.4k
Disposed/sold 15,643 options to buy
@ $22.78, valued at
$356.3k
|
|
| 02/25/2019 |
4
| MOORE CRAIG W (Director) has filed a Form 4 on NxStage Medical, Inc.|
Txns:
| Disposed/sold 3,745 shares
@ $30, valued at
$112.4k
Disposed/sold 105,439 shares
@ $30, valued at
$3.2M
Disposed/sold 23,394 options to buy
@ $13.16, valued at
$307.9k
Disposed/sold 19,724 options to buy
@ $16.81, valued at
$331.6k
Disposed/sold 15,854 options to buy
@ $18.32, valued at
$290.4k
Disposed/sold 15,643 options to buy
@ $22.78, valued at
$356.3k
|
|
| 02/25/2019 |
4
| Donigan Heyward R (Director) has filed a Form 4 on NxStage Medical, Inc.|
Txns:
| Disposed/sold 3,582 shares
@ $30, valued at
$107.5k
Disposed/sold 10,784 options to buy
@ $21.73, valued at
$234.3k
Disposed/sold 15,643 options to buy
@ $22.78, valued at
$356.3k
|
|
| 02/25/2019 |
4
| REID PERPER (Director) has filed a Form 4 on NxStage Medical, Inc.|
Txns:
| Disposed/sold 145,826 shares
@ $30, valued at
$4.4M
Disposed/sold 23,394 options to buy
@ $13.16, valued at
$307.9k
Disposed/sold 15,854 options to buy
@ $18.32, valued at
$290.4k
Disposed/sold 15,643 options to buy
@ $22.78, valued at
$356.3k
Disposed/sold 19,724 options to buy
@ $16.81, valued at
$331.6k
|
|
| 02/25/2019 |
4
| Giannini Daniel A (Director) has filed a Form 4 on NxStage Medical, Inc.|
Txns:
| Disposed/sold 81,389 shares
@ $30, valued at
$2.4M
Disposed/sold 23,394 options to buy
@ $13.16, valued at
$307.9k
Disposed/sold 19,724 options to buy
@ $16.81, valued at
$331.6k
Disposed/sold 15,854 options to buy
@ $18.32, valued at
$290.4k
Disposed/sold 15,643 options to buy
@ $22.78, valued at
$356.3k
|
|
| 02/25/2019 |
4
| FUNARI ROBERT G (Director) has filed a Form 4 on NxStage Medical, Inc.|
Txns:
| Disposed/sold 22,837 shares
@ $30, valued at
$685.1k
Disposed/sold 23,394 options to buy
@ $13.16, valued at
$307.9k
Disposed/sold 19,724 options to buy
@ $16.81, valued at
$331.6k
Disposed/sold 15,854 options to buy
@ $18.32, valued at
$290.4k
Disposed/sold 15,643 options to buy
@ $22.78, valued at
$356.3k
|
|
| 02/25/2019 |
4
| LEWIS EARL R (Director) has filed a Form 4 on NxStage Medical, Inc.|
Txns:
| Disposed/sold 100,232 shares
@ $30, valued at
$3M
Disposed/sold 23,394 options to buy
@ $13.16, valued at
$307.9k
Disposed/sold 19,724 options to buy
@ $16.81, valued at
$331.6k
Disposed/sold 15,854 options to buy
@ $18.32, valued at
$290.4k
Disposed/sold 15,643 options to buy
@ $22.78, valued at
$356.3k
|
|
| 02/25/2019 |
4
| Peters James J (Director) has filed a Form 4 on NxStage Medical, Inc.|
Txns:
| Disposed/sold 15,643 options to buy
@ $22.78, valued at
$356.3k
Disposed/sold 17,537 options to buy
@ $19.03, valued at
$333.7k
|
|
| 02/22/2019 |
S-8 POS
| Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments: |
| 02/22/2019 |
S-8 POS
| Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments: |
| 02/22/2019 |
S-8 POS
| Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments: |
| 02/22/2019 |
S-8 POS
| Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments: |
| 02/22/2019 |
S-8 POS
| Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments: |
| 02/22/2019 |
S-8 POS
| Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments: |
| 02/22/2019 |
S-8 POS
| Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments: |
| 02/22/2019 |
S-8 POS
| Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments: |
| 02/22/2019 |
S-8 POS
| Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments: |
| 02/22/2019 |
25-NSE
| Form 25-NSE - Notification filed by national security exchange to report the removal from listing and registration of matured, redeemed or retired securities: |
| 02/22/2019 |
8-K
| Quarterly results |
| 02/14/2019 |
SC 13G
| Form SC 13G - Statement of acquisition of beneficial ownership by individuals: |
| 02/14/2019 |
SC 13G
| TIG Advisors, LLC reports a 5.9% stake in NxStage Medical, Inc. |
|
|
|